CRP and obesity disorder: A recent 12-week RCT evaluated the effects of adjunctive intravenous infliximab for the treatment of bipolar depression in patients with biochemical (i.e. elevated CRP ≥ 5 mg/L) or phenotypical (i.e. obesity, diabetes type 1 or 2, inflammatory bowel disease, rheumatological disorder, daily cigarette smoking, or migraine headaches) evidence of inflammation.